# Combined Treatment With Nivolumab and Trabectedin in Patients With Metastatic or Inoperable Soft Tissue Sarcomas

> **NCT03590210** · PHASE2 · COMPLETED · sponsor: **University Medicine Greifswald** · enrollment: 92 (actual)

## Conditions studied

- Metastatic Adult Soft Tissue Sarcoma

## Interventions

- **DRUG:** Trabectedin
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT03590210
- **Lead sponsor:** University Medicine Greifswald
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-08
- **Primary completion:** 2022-02-12
- **Final completion:** 2022-02-12
- **Target enrollment:** 92 (ACTUAL)
- **Last updated:** 2022-11-08

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03590210

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03590210, "Combined Treatment With Nivolumab and Trabectedin in Patients With Metastatic or Inoperable Soft Tissue Sarcomas". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03590210. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*